An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 [blinatumomab] in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL).

Trial Profile

An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 [blinatumomab] in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL).

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 06 Dec 2016 Results assessing Blinatumomab associated Neurologic Events in NCT00274742, NCT00560794, NCT01209286, NCT01471782, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Jun 2016 Results of the QSP model accessing MoA of blinatumomab presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 12 May 2016 Results (pooled analysis of this and other five studies) assessing PK and PD of blinatumomab published in the Clinical Pharmacokinetics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top